Studies of Left Ventricular Dysfunction (SOLVD) - Allie: Abbreviation / Long Form Info.

■ Abbreviation / Long Form : SOLVD / Studies of Left Ventricular Dysfunction

[Related PubMed/MEDLINE]
Total Number of Papers: 119

[Display Entries]

>> all entries

[Entries Per Page]

per page

Page Control

Page: of

Abbreviation:	SOLVD (>> Co-occurring Abbreviation)
Long Form:	Studies of Left Ventricular Dysfunction

Abbreviation Variation

Long Form Variation

Pair(Abbreviation/Long Form) Variation

No.	Year	Title	Co-occurring Abbreviation
1	2022	Estimated quadratic inference function for correlated failure time data.	---
2	2019	Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.	eGFR
3	2019	Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial.	CIs, HRs
4	2019	Semiparametric Additive Model for Estimating Risk Difference in Multicenter Studies.	---
5	2019	Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.	ACE, eGFR, HFrEF
6	2017	Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.	ACE, CI, HFrEF, HR
7	2016	The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio.	eGFR, RD
8	2012	Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.	CI, CKD, HR, SHF
9	2011	Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials.	BEST, CI, GFR, HR, RI
10	2011	Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction.	ACEi, GFR, HR, WRF
11	2010	Multivariate Failure Times Regression with a Continuous Auxiliary Covariate.	---
12	2010	Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction.	CI, HR, SOLVD-PT
13	2008	Comparing estimates of influenza-associated hospitalization and death among adults with congestive heart failure based on how influenza season is defined.	CI, HR
14	2008	Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD.	CV, HF
15	2007	Anemia as a risk factor for kidney function decline in individuals with heart failure.	CKD, GFR, MDRD
16	2007	Mitral insufficiency and morbidity and mortality in left ventricular dysfunction.	---
17	2006	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.	---
18	2006	Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure.	CHF, CI, HR, RR
19	2005	Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.	ACEIs, CI, HR, OR
20	2005	The effect of gender on outcome in digitalis-treated heart failure patients.	---
21	2005	The impact of race on response to RAAS inhibition.	ACE, V-HeFT
22	2004	Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.	HF
23	2004	Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.	ACE, LV
24	2004	Racial response to angiotensin-converting enzyme therapy in systolic heart failure.	---
25	2003	A regression-based method for estimating mean treatment cost in the presence of right-censoring.	HMO, KM, PL
26	2003	Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).	ACE, CI, HF, PSDs, RR
27	2003	Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.	---
28	2003	Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.	ACEI, AF, HF, MHI
29	2003	Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).	ACE, FPG
30	2003	Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.	MERIT-HF, RALES
31	2003	Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD).	---
32	2003	The prognostic value of the physical examination in patients with chronic heart failure.	---
33	2003	The utility of multidimensional assessments of physical health in patient care.	---
34	2003	Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction.	CI, RR
35	2002	Angiotensin II and trials of cardiovascular outcomes.	ACE, AIRE, CCS, CONSENSUS-I, GISSI, HOPE, MI, SAVE, TRACE
36	2002	Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).	ACE, NEP
37	2002	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.	ACE
38	2002	Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis.	CI, HOPE, WATCH
39	2002	Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?	ACE, CATS, MI
40	2002	The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.	---
41	2001	Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.	---
42	2001	Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction.	CABG, EF
43	2001	Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.	CI, RR
44	2001	Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.	CI, LVEF, MI, RR
45	2000	Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction.	CV, EF, LA, LV, NYHA
46	2000	Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction.	CHF, LV, NYHA
47	2000	Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction.	LV
48	2000	Predictors of quality of life in women with heart failure. SOLVD Investigators. Studies of Left Ventricular Dysfunction.	HF, NYHA, QoL
49	2000	Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.	---
50	2000	The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.	RR
51	1999	Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.	ACE
52	1999	Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction).	EF, LV, RNA
53	1999	Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.	RR
54	1999	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)	CHF, CI, RR
55	1999	Racial differences in the outcome of left ventricular dysfunction.	---
56	1999	The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction.	ACE
57	1999	White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD])	LV, RR, WBC
58	1998	Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.	APA, CI, HF, HR, LV
59	1998	Evidence-based medicine and ACE inhibition.	ACE, CAD, CHF, LV, MI, SAVE
60	1998	Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.	ACE, CONSENSUS, SAVE, TREND, V-HeFT I
61	1998	Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction.	CI, HR, LV
62	1997	Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction.	CCB, CI, LVD, MI, RR
63	1997	Determinants of perceived health in patients with left ventricular dysfunction: a structural modeling analysis.	---
64	1997	Estimating the mean hazard ratio parameters for clustered survival data with random clusters.	---
65	1996	Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators.	LVD
66	1996	Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.	CHF, HRQL, RR
67	1996	Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.	---
68	1996	Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction.	HF
69	1996	Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.	ANP, PNE
70	1996	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).	---
71	1996	The changing face of hypertension and antihypertensive agents.	---
72	1996	[Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain].	---
73	1996	[New aspects of ACE inhibitor treatment of heart failure].	SAVE
74	1995	Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.	---
75	1995	Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators.	ANP, LV, NE
76	1995	Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.	LV
77	1995	Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure.	ACE, CHF, SAVE
78	1995	Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators.	---
79	1995	Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD).	ACEi
80	1995	Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis.	SAVE
81	1995	Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.	ACE, AIRE, CONSENSUS-II, SAVE
82	1995	The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction.	DBP, RR, SBP
83	1994	Angiotensin converting enzyme inhibition and coronary artery disease.	ACE, AIRE, GISSI-3, QUIET, SAVE
84	1994	Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials.	ACE, CONSENSUS, SAVE
85	1994	Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.	ACE, SAVE
86	1994	Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.	ACE, CHF, CONSENSUS, VH eFT-II
87	1994	Optimizing the treatment of heart failure.	ACE
88	1994	Patient perception of a long-term clinical trial: experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial. SOLVD Close-out Working Group.	---
89	1994	Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.	---
90	1994	Reduced peak aerobic capacity in asymptomatic left ventricular systolic dysfunction. A substudy of the studies of left ventricular dysfunction (SOLVD). SOLVD Investigator. Studies of Left Ventricular Dysfunction.	---
91	1994	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.	---
92	1993	Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy.	---
93	1993	Calcium antagonists or beta-blockers in chronic ischaemic left ventricular dysfunction?	ACE, LVD
94	1993	Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators.	---
95	1993	Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.	ACE, EDV, EF, LV
96	1993	Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials.	---
97	1993	Lessons from recent randomized controlled trials for the management of congestive heart failure.	ACE, CONSENSUS, V-HeFT II
98	1993	Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators.	---
99	1993	Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.	---
100	1993	Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.	ACE, CI